Peer-reviewed journals rejected their followup study on the 2023-2024 formulation of mRNA vaccines against the JN.1 variant of SARS-CoV-2, which found their "low level of protection" was offset by the ...

Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because of its high incidence in North America ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

TUESDAY, April 8, 2025 (HealthDay News) -- Federal cuts to funding could “decimate” medical research in the United States, ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...

New vaccines to control tuberculosis (TB) are urgently needed to fight the global burden of the disease, the increase of resistant strains and the lack of effective vaccines to prevent latent TB ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer ...

Heidelberg biochemists and structural biologists from Shanghai unravel the roles of two key regulatory factors in mRNA ...

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

Kim V. Narry, director of the Center for RNA Research of the Institute for Basic Science and chair professor at the ...